CANTA — Cantargia AB Share News
0.000.00%
Last trade - 00:00- SEK399.02m
- SEK177.07m
- SEK316.70m
Brief: Cantargia Says Preclinical Data Supports Nadunolimab In PDAC
Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Brief: Cantargia H1 EBIT SEK -72.7 Million
Brief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML
Sweden's Cantargia 2025 sales rise but miss analyst expectations
Brief: Cantargia Does Not Intend To Propose Dividend
Brief: Cantargia Updates On Results From Trifour Study In TNBC
Brief: Cantargia 9M EBIT SEK 182.5 Million
Brief: Cantargia Granted Important Us Patent For Nadunolimab
Brief: Cantargia H1 EBIT SEK -84.5 Million
Brief: Cantargia Appoints Dr Hilde Steineger As CEO
Brief: Cantargia Reports Similar Efficacy For Its Drug And Chemo In Trial
Brief: Cantargia, Otsuka Sign Deal On Rights For Development Of CAN10 Il1rap Immunology Program
Brief: FDA Grants Fast Track Designation To Cantargia's Nadunolimab For Metastatic Pdac
Brief: Cantargia Publishes Preclinical Results Highlighting Can10's Potential To Inhibit Vascular Inflammation